Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial
Official title:
The Pilot Palliative ARNP (Advanced Registered Nurse Practitioner) Liaison Program (The PAL Program): Improving Communication Between Patients, Oncologists, and Hospice, Promoting Timely Hospice Referrals and Bringing Education and Research Efforts to Hospice and Palliative Care
RATIONALE: Gathering information about patients with terminal metastatic cancer may help
doctors learn more about the effectiveness of a nurse practitioner hospice program. It is not
yet known whether a nurse practitioner program helps increase patients' length of stay in
hospice.
PURPOSE: This randomized research study is evaluating a nurse practitioner hospice program
for patients with terminal metastatic cancer and their families or caregivers.
OBJECTIVES:
Primary
- To assess the effect of the palliative advanced registered nurse practitioner liaison
program (PAL) on length of patient's enrollment in hospice care.
Secondary
- To evaluate the impact of the PAL program on patient's knowledge about hospice services.
- To evaluate the impact of the PAL program on patient and family or caregiver's
psychological stress during palliative treatments.
OUTLINE: Patients are randomized to 1 of 2 arms.
- Arm I (advanced registered nurse practitioner [ARNP] intervention): Patients and their
families or caregiver receive information from an ARNP about terminal cancer, resources
available for supportive care, and the benefits of palliative care. After transition to
hospice, patients receive pain and palliative medicine, psychology, social services,
chaplaincy, and patient support group intervention arranged by the ARNP. Patients
complete the Patient Questionnaire about overall quality of life and mental, emotional,
and physical well being at baseline and at 3 weeks after intervention or at time of
enrollment in hospice. Patients and their families or caregivers are contacted by the
ARNP weekly.
- Arm II (no ARNP intervention): Patients and their families or caregivers complete the
same Patient Questionnaire, administered by a clinical research assistant (CRA), as in
Arm I. Patients and their families or caregivers receive no ARNP intervention. After
transition to hospice, patients receive routine hospice care.
Patients participate in this study for a duration of 21 days while in hospice care. At the
completion of the study, patients in both arms complete questionnaires about pain management,
social, emotional, and spiritual and mental well-being. Patients' families or caregivers
complete the Caregiver Questionnaire and the Hospice Family Satisfaction Survey 3 weeks after
patient's death.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01828775 -
Palliative Care Intervention in Improving Quality of Life, Psychological Distress, and Communication in Patients With Solid Tumors Receiving Treatment
|
N/A | |
| Terminated |
NCT01642342 -
Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors
|
Phase 1 | |
| Completed |
NCT00002950 -
Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT01705548 -
Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis
|
N/A | |
| Completed |
NCT02146222 -
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors
|
Phase 1 | |
| Terminated |
NCT01602627 -
Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies
|
Phase 1 | |
| Completed |
NCT01191216 -
1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT01137825 -
Registry of Older Patients With Cancer
|
||
| Recruiting |
NCT00992303 -
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
|
||
| Completed |
NCT00949949 -
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
|
Phase 1 | |
| Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
| Completed |
NCT00924651 -
Exercise in Lessening Fatigue Caused by Cancer in Patients Undergoing Chemotherapy
|
Phase 3 | |
| Withdrawn |
NCT00937417 -
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT00710632 -
Screening to Predict Weight Loss in Patients With Cancer
|
N/A | |
| Completed |
NCT00573690 -
Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT00544596 -
R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT00436735 -
Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors
|
Phase 1 | |
| Completed |
NCT00352443 -
S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
|
Phase 1 | |
| Completed |
NCT00126620 -
Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors
|
Phase 1 | |
| Completed |
NCT00255658 -
Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors
|
Phase 1 |